Trovagene Inc. (NASDAQ:TROV) traded down 1% during trading on Friday . The company traded as low as $4.88 and last traded at $4.91, with a volume of 111,237 shares changing hands. The stock had previously closed at $4.96.

A number of equities research analysts have commented on the company. Zacks Investment Research raised Trovagene from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Wednesday, August 24th. Cantor Fitzgerald raised Trovagene from a “hold” rating to a “buy” rating and raised their price objective for the company from $5.00 to $7.00 in a research note on Monday, August 8th. Piper Jaffray Cos. set a $4.00 price objective on Trovagene and gave the company a “hold” rating in a research note on Friday, August 5th. Maxim Group lifted their target price on Trovagene from $9.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Leerink Swann reaffirmed a “hold” rating on shares of Trovagene in a research report on Thursday, May 12th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $7.13.

The firm’s market capitalization is $149.53 million. The company’s 50-day moving average price is $5.30 and its 200-day moving average price is $5.04.

Trovagene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.03. On average, equities research analysts forecast that Trovagene Inc. will post ($1.34) earnings per share for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.